Half-year report · HY
7133.TEDINET S100X2MF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥10.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥226m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥449m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥206m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥435m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥205m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥435m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥136m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥719m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥291m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥136m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥291m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.2bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥7.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.4bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥754m | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥566m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥754m | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥566m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥889m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥688m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥134m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥771m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥188m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥527m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥474m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥188m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥849m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥419m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥201m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.1 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.03 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥18.55 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥97.92 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥39.62 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 28.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥373,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥373,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥18m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥298m |
| Home Visit Pharmacist Servicereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥228m |
| Kirari Primereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥591m |
| Kirari Primereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥591m |
| Kirari Primereportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥342m |
| Primary Care Homereportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Primary Care Homereportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.0bn |
| Primary Care Homereportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥28m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥542m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥524m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥420,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥420,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥296m |
| Home Visit Pharmacist Servicereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| Home Visit Pharmacist Servicereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.4bn |
| Home Visit Pharmacist Servicereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥277m |
| Kirari Primereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥544m |
| Kirari Primereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥544m |
| Kirari Primereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥338m |
| Primary Care Homereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥759m |
| Primary Care Homereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥759m |
| Primary Care Homereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥134m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥749m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥745m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 455
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |